- $3.14bn
- $1.88bn
- $630.20m
- 50
- 61
- 64
- 61
RCS - Hutchmed China Ltd - HUTCHMED to Receive Milestone Payment from Takeda
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce ELUNATE Approval
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Continued Inclusion of ORPATHYS in China NRDL
AnnouncementRCS - Hutchmed China Ltd - FRUZAQLA® Launched in Japan by Takeda
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - First Commercial Milestone Payment
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementREG - Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate
AnnouncementREG - Hutchmed China Ltd - Japan Approval for FRUZAQLA
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ESMO and WCLC
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Update on Fruquintinib for Gastric Cancer in China
AnnouncementREG - Hutchmed China Ltd - Standard form for notification of major holdings
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Host Expert Call to discuss ITP
AnnouncementREG - Hutchmed China Ltd - LTIP and Share Option Scheme
Announcement